
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11017760/publications.pdf Version: 2024-02-01



\λ/λιτερ Ερλττλ

#	Article	IF	CITATIONS
1	Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. International Journal of Molecular Sciences, 2021, 22, 1863.	1.8	60
2	Analysis of Opioid-Seeking Behavior Through the Intravenous Self-Administration Reinstatement Model in Rats. Methods in Molecular Biology, 2021, 2201, 231-245.	0.4	3
3	Conditioned Place Preference (CPP) in Rats: From Conditioning to Reinstatement Test. Methods in Molecular Biology, 2021, 2201, 221-229.	0.4	5
4	Altered brain levels of arachidonic acid-derived inflammatory eicosanoids in a rodent model of anorexia nervosa. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158578.	1.2	8
5	Cannabinoid exposure in rat adolescence reprograms the initial behavioral, molecular, and epigenetic response to cocaine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9991-10002.	3.3	39
6	Cannabinoids and their therapeutic applications in mental disorders. Dialogues in Clinical Neuroscience, 2020, 22, 271-279.	1.8	13
7	Brain activity of anandamide: a rewarding bliss?. Acta Pharmacologica Sinica, 2019, 40, 309-323.	2.8	53
8	Impaired brain endocannabinoid tone in the activityâ€based model of anorexia nervosa. International Journal of Eating Disorders, 2019, 52, 1251-1262.	2.1	19
9	Sex-specific differences in cannabinoid-induced extracellular-signal-regulated kinase phosphorylation in the cingulate cortex, prefrontal cortex, and nucleus accumbens of Lister Hooded rats. Behavioural Pharmacology, 2018, 29, 473-481.	0.8	8
10	Cannabinoid Modulation of Eukaryotic Initiation Factors (eIF2α and eIF2B1) and Behavioral Cross-Sensitization to Cocaine in Adolescent Rats. Cell Reports, 2018, 22, 2909-2923.	2.9	23
11	Levodopa prevents the reinstatement of cocaine selfâ€administration in rats via potentiation of dopamine release in the medial prefrontal cortex. Addiction Biology, 2018, 23, 556-568.	1.4	10
12	Sex and Feeding Status Differently Affect Natural Reward Seeking Behavior in Olfactory Bulbectomized Rats. Frontiers in Behavioral Neuroscience, 2018, 12, 255.	1.0	7
13	New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. Medicines (Basel,) Tj ETQq1	1 0.78431 0.7	.4 rgBT /Ove
14	Limited Access to a High Fat Diet Alters Endocannabinoid Tone in Female Rats. Frontiers in Neuroscience, 2018, 12, 40.	1.4	19
15	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ Open, 2017, 7, e014938.	0.8	5
16	Cannabinoid CB <sub>1</sub> /CB <sub>2</sub> receptor agonists attenuate hyperactivity and body weight loss in a rat model of activityâ€based anorexia. British Journal of Pharmacology, 2017, 174, 2682-2695.	2.7	33
17	The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB1 receptor density and function. Pharmacological Research, 2017, 115, 209-217.	3.1	12
18	Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behavioural Pharmacology, 2016, 27, 489-496.	0.8	26

#	Article	IF	CITATIONS
19	Elevated dopamine in the medial prefrontal cortex suppresses cocaine seeking via <scp>D</scp> 1 receptor overstimulation. Addiction Biology, 2016, 21, 61-71.	1.4	13
20	Emotional profile of female rats showing binge eating behavior. Physiology and Behavior, 2016, 163, 136-143.	1.0	12
21	Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology, 2016, 233, 1765-1777.	1.5	39
22	Adolescent Δ9-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats. Neuropsychopharmacology, 2016, 41, 1416-1426.	2.8	53
23	Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology, 2015, 232, 91-100.	1.5	15
24	Role of Opioid Receptors in the Reinstatement of Opioid-Seeking Behavior: An Overview. Methods in Molecular Biology, 2015, 1230, 281-293.	0.4	6
25	Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Frontiers in Pharmacology, 2014, 5, 44.	1.6	32
26	Sex differences in addictive disorders. Frontiers in Neuroendocrinology, 2014, 35, 272-284.	2.5	211
27	Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing to Drug Addiction: Effect of Ovarian Hormones. Current Pharmaceutical Design, 2014, 20, 2100-2113.	0.9	108
28	Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology, 2013, 225, 531-542.	1.5	21
29	Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nature Neuroscience, 2013, 16, 1652-1661.	7.1	85
30	PPARα Regulates Cholinergic-Driven Activity of Midbrain Dopamine Neurons via a Novel Mechanism Involving α7 Nicotinic Acetylcholine Receptors. Journal of Neuroscience, 2013, 33, 6203-6211.	1.7	79
31	Molecular mechanisms of cannabinoid addiction. Current Opinion in Neurobiology, 2013, 23, 487-492.	2.0	36
32	AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. Journal of Psychopharmacology, 2013, 27, 564-571.	2.0	31
33	The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotineâ€induced dopamine elevations in the nucleus accumbens shell in rats. British Journal of Pharmacology, 2012, 165, 2539-2548.	2.7	56
34	Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. Biological Psychiatry, 2011, 69, 633-641.	0.7	112
35	Beyond THC: The New Generation of Cannabinoid Designer Drugs. Frontiers in Behavioral Neuroscience, 2011, 5, 60.	1.0	360
36	How important are sex differences in cannabinoid action?. British Journal of Pharmacology, 2010, 160, 544-548.	2.7	156

#	Article	IF	CITATIONS
37	Peroxisome Proliferator-Activated Receptors-Alpha Modulate Dopamine Cell Activity Through Nicotinic Receptors. Biological Psychiatry, 2010, 68, 256-264.	0.7	92
38	The endocannabinoid system and nondrug rewarding behaviours. Experimental Neurology, 2010, 224, 23-36.	2.0	78
39	Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. European Neuropsychopharmacology, 2010, 20, 25-36.	0.3	54
40	Sex differences in the self-administration of cannabinoids and other drugs of abuse. Psychoneuroendocrinology, 2009, 34, S227-S236.	1.3	71
41	Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. European Neuropsychopharmacology, 2009, 19, 487-498.	0.3	58
42	Sex Differences in Drug Addiction: A Review of Animal and Human Studies. Women's Health, 2008, 4, 51-65.	0.7	160
43	Involvement of κ-Opioid and Endocannabinoid System on Salvinorin A-Induced Reward. Biological Psychiatry, 2008, 63, 286-292.	0.7	89
44	Changed accumbal responsiveness to alcohol in rats pre-treated with nicotine or the cannabinoid receptor agonist WIN 55,212-2. Neuroscience Letters, 2008, 433, 1-5.	1.0	19
45	The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology, 2008, 54, 129-140.	2.0	132
46	The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction. CNS and Neurological Disorders - Drug Targets, 2008, 7, 468-481.	0.8	32
47	Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 482-490.	1.3	132
48	Nicotinic Facilitation of Δ9-Tetrahydrocannabinol Discrimination Involves Endogenous Anandamide. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1127-1134.	1.3	40
49	Nicotinic Â7 Receptors as a New Target for Treatment of Cannabis Abuse. Journal of Neuroscience, 2007, 27, 5615-5620.	1.7	83
50	A possible role for the endocannabinoid system in the neurobiology of depression. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 25.	0.6	43
51	Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology, 2007, 52, 646-654.	2.0	67
52	The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology, 2007, 52, 1555-1562.	2.0	60
53	Endocannabinoid regulation of relapse mechanisms. Pharmacological Research, 2007, 56, 418-427.	3.1	47
54	Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55 212-2 European Journal of Neuroscience, 2007, 25, 2191-2200	1.2	74

#	Article	IF	CITATIONS
55	An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives. Brain Research Reviews, 2007, 53, 1-16.	9.1	90
56	Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts. Behavioural Brain Research, 2006, 168, 307-311.	1.2	28
57	Cannabinoid self-administration increases dopamine release in the nucleus accumbens. NeuroReport, 2006, 17, 1629-1632.	0.6	101
58	Endocannabinoid system and opioid addiction: Behavioural aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 343-359.	1.3	97
59	Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology, 2005, 48, 1097-1104.	2.0	82
60	CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. British Journal of Pharmacology, 2004, 143, 343-350.	2.7	84
61	Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology, 2004, 47, 1170-1179.	2.0	98
62	Cannabinoids and Reward: Interactions with the Opioid System. Critical Reviews in Neurobiology, 2004, 16, 147-158.	3.3	95
63	Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse, 2003, 50, 1-6.	0.6	184
64	BACLOFEN ANTAGONIZES INTRAVENOUS SELF-ADMINISTRATION OF NICOTINE IN MICE AND RATS. Alcohol and Alcoholism, 2002, 37, 495-498.	0.9	88
65	Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research, 2001, 118, 61-65.	1.2	254
66	Baclofen antagonises intravenous self-administration of Î <sup>3</sup> -hydroxybutyric acid in mice. NeuroReport, 2001, 12, 2243-2246.	0.6	27
67	Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology, 2001, 156, 410-416.	1.5	180
68	The cyclo-oxygenase inhibitor nimesulide induces conditioned place preference in rats. European Journal of Pharmacology, 2000, 406, 75-77.	1.7	6
69	Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB1 receptor knockout mice. European Journal of Pharmacology, 1999, 383, R1-R2.	1.7	110
70	Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB1 Receptor Knockout Mice. Science, 1999, 283, 401-404.	6.0	2,225
71	CB1 cannabinoid receptor agonist WIN 55,â€^212-2 decreases intravenous cocaine self-administration in rats. Behavioural Brain Research, 1999, 104, 141-146.	1.2	94
72	Gamma-Hydroxybutyric Acid Decreases Intravenous Cocaine Self-Administration in Rats. Pharmacology Biochemistry and Behavior, 1998, 59, 697-702.	1.3	12

#	Article	IF	CITATIONS
73	STRESS-INDUCED SLEEP DEPRIVATION MODIFIES CORTICOTROPIN RELEASING FACTOR (CRF) LEVELS AND CRF BINDING IN RAT BRAIN AND PITUITARY. Pharmacological Research, 1997, 35, 443-446.	3.1	67
74	C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures. , 1996, 24, 297-304.		5
75	Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. Pharmacology Biochemistry and Behavior, 1995, 52, 271-274.	1.3	50
76	Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats. Psychopharmacology, 1994, 113, 378-380.	1.5	41
77	Fidia and neuroscience. Nature, 1993, 366, 399-399.	13.7	2
78	Clonidine Prevents Corticotropin Releasing Factor-Induced Epileptogenic Activity in Rats. Epilepsia, 1992, 33, 435-438.	2.6	5
79	Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacology Biochemistry and Behavior, 1992, 41, 497-500.	1.3	96
80	Neonatal Monosodium Glutamate Abolishes Corticotropinâ€Releasing Factorâ€Induced Epileptogenic Activity in Rats. Epilepsia, 1990, 31, 708-712.	2.6	4
81	Corticotropin-releasing factor (CRF) increases paradoxical sleep (PS) rebound in PS-deprived rats. Brain Research, 1990, 515, 315-318.	1.1	50
82	Localized Epileptiform Activity Induced by Murine CRF in Rats. Epilepsia, 1988, 29, 369-373.	2.6	52
83	Stress-induced insomnia: opioid-dopamine interactions. European Journal of Pharmacology, 1987, 142, 437-440.	1.7	50